% | $
Quotes you view appear here for quick access.

The Madison Square Garden Company Message Board

koufax62 3 posts  |  Last Activity: Sep 23, 2015 12:01 AM Member since: Nov 16, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • koufax62 by koufax62 Sep 23, 2015 12:01 AM Flag


    Based on recent news flow (DHHS planned regulation changes bolstered by the Tenncare deal putting a serious dent in the LT Bunavail sales trajectory short thesis. Nice to be acknowledged as the "good guy" amidst the latest round of Washington pharma price gouging rhetoric.

    Also based on probably an 80%+ chance of FDA clearance for Bel, a lucrative royalty rate, and milestone payout that oblitirates any balance sheet concerns along with the overhang.

    IMO, if the major holder ETF's are pressured by the broader markets and IBB weakness, a well above average opportunity to accumulate on the cheap or possibly even cheaper has now materialized for anyone following the BDSI story.

    From a valuation standpoint and factoring the above, anything under 500M would appear very compelling. Sub 400M MC from my viewpoint looks like outstanding value!

    JMHO & 2 cents!


  • koufax62 koufax62 Aug 10, 2015 10:24 PM Flag

    Shopping for an island Aezs?

    Here's a slogan for ya, freshly minted out of Madison ave.

    Rikers Island and low life spamsters,,,,,,,,,Perfect together!



  • koufax62 by koufax62 Dec 17, 2014 7:35 PM Flag

    Cash preserving personnel cuts to extend the on hand working capital runway thru P3 data & beyond into CY'16 on it's own looks like SOP, but combined with Nov positive P2 end point achieve plus auction of pre-clinic equipment has the feel of a bare bones reduction to just clinical pipeline/ongoing trials to be packaged to SD or other entity.

    Cut away all the non-essentials in prep for the large acquiring player closing the deal.

    IMO, the stock should have popped to 1.80-2.00 just on the recent data released in Nov + cash (Jan effect delayed reaction?) not including the SD partnership/asset so 300M+ in it's entirety appears well within the realm of reason.

    Any comments?

162.46-3.34(-2.01%)Nov 30 4:02 PMEST